RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Onconova Therapeutics Stock

Onconova Therapeutics EBIT 2024

Onconova Therapeutics EBIT

-24.89 M USD

Ticker

ONTX

ISIN

US68232V4059

WKN

A2N6RH

In 2024, Onconova Therapeutics's EBIT was -24.89 M USD, a 22.61% increase from the -20.3 M USD EBIT recorded in the previous year.

The Onconova Therapeutics EBIT history

YEAREBIT (undefined USD)
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-
2014-
2013-
2012-
2011-

Onconova Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Onconova Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Onconova Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Onconova Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Onconova Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Onconova Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Onconova Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Onconova Therapeutics’s growth potential.

Onconova Therapeutics Revenue, EBIT and net profit per share

DateOnconova Therapeutics RevenueOnconova Therapeutics EBITOnconova Therapeutics Net Income
2026e195,935.3 undefined-14.02 M undefined-17.99 M undefined
2025e306,000 undefined-30.29 M undefined-18.42 M undefined
2024e265,200 undefined-24.89 M undefined-18.85 M undefined
2023226,000 undefined-20.3 M undefined-18.95 M undefined
2022226,000 undefined-19.63 M undefined-18.96 M undefined
2021226,000 undefined-16.5 M undefined-16.16 M undefined
2020230,000 undefined-24.99 M undefined-25.16 M undefined
20192.18 M undefined-21.7 M undefined-21.5 M undefined
20181.23 M undefined-23.28 M undefined-20.57 M undefined
2017790,000 undefined-25.74 M undefined-24.09 M undefined
20165.55 M undefined-23.7 M undefined-19.67 M undefined
201511.46 M undefined-23.97 M undefined-23.98 M undefined
2014800,000 undefined-63.74 M undefined-63.68 M undefined
20134.75 M undefined-62.22 M undefined-64.86 M undefined
201246.19 M undefined-22.28 M undefined-33.87 M undefined
20111.49 M undefined-27.57 M undefined-30.31 M undefined

Onconova Therapeutics stock margins

The Onconova Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Onconova Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Onconova Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Onconova Therapeutics's sales revenue. A higher gross margin percentage indicates that the Onconova Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Onconova Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Onconova Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Onconova Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Onconova Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Onconova Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Onconova Therapeutics Margin History

Onconova Therapeutics Gross marginOnconova Therapeutics Profit marginOnconova Therapeutics EBIT marginOnconova Therapeutics Profit margin
2026e0 %-7,152.91 %-9,183.03 %
2025e0 %-9,900 %-6,020 %
2024e0 %-9,384.62 %-7,107.69 %
20230 %-8,981.42 %-8,384.07 %
20220 %-8,684.51 %-8,391.15 %
20210 %-7,299.12 %-7,151.77 %
20200 %-10,865.22 %-10,939.13 %
20190 %-995.41 %-986.24 %
20180 %-1,892.68 %-1,672.36 %
20170 %-3,258.23 %-3,049.37 %
20160 %-427.03 %-354.41 %
20150 %-209.16 %-209.25 %
20140 %-7,967.5 %-7,960 %
20130 %-1,309.89 %-1,365.47 %
20120 %-48.24 %-73.33 %
20110 %-1,850.34 %-2,034.23 %

Onconova Therapeutics Aktienanalyse

What does Onconova Therapeutics do?

Onconova Therapeutics Inc. is a biopharmaceutical company focused on the development of drugs and therapies for the treatment of cancer. The company was founded in Pennsylvania in 1998 and is headquartered in Newtown, Pennsylvania. In 2013, the company went public and was listed on the NASDAQ. The history of Onconova Therapeutics began with the discovery of a new class of compounds known as precursor nucleotide analogs. These compounds were developed in collaboration with the National Cancer Institute (NCI) and showed promising results in cancer treatment. Onconova aims to develop innovative cancer therapies that allow for targeted attack on cancer cells without damaging healthy cells in the body. The company's research and development efforts focus on the discovery and development of new compounds and therapy approaches, as well as improving existing cancer treatments. The business model of Onconova Therapeutics is centered around building long-term partnerships with leading pharmaceutical companies, academic institutions, and research facilities. The company works closely with these partners to develop innovative therapies and drugs that meet the needs of cancer patients. Onconova has divided its product development into multiple areas to investigate the potential of its compounds in various therapy areas. The two main areas of focus for the company are myeloproliferative neoplasms (MPN) and oncology. Myeloproliferative neoplasms are a group of blood cancers that affect the bone marrow. Onconova Therapeutics has developed a promising class of compounds known as selective oral inhibitors (SOIs) that target the main drivers of MPNs and have shown positive results in clinical trials. The oncology division of the company focuses on the development of compounds for the treatment of solid tumors. Onconova has developed a targeted cancer therapy that focuses on inhibiting WNT signaling. This approach aims to allow for selective attack on cancer cells without damaging healthy cells in the body. In addition to these two areas, the company is also working on the development of compounds for the treatment of advanced tumors, lung cancer, and other types of cancer. The main product of Onconova Therapeutics is Rigosertib. Rigosertib is a selective oral inhibitor (SOI) specifically developed for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The drug is currently in the final phase III of testing by the FDA. In addition to Rigosertib, Onconova is conducting further clinical studies to investigate the effectiveness and safety of its cancer drugs. The company aims to develop innovative therapy options that help cancer patients overcome their disease and lead longer lives without the harmful effects of conventional cancer therapies. Overall, Onconova Therapeutics Inc. has a promising future as an innovative biopharmaceutical company. By continuing its research and development activities in multiple areas and developing new compounds and therapies, Onconova will continually contribute to improving the lives of cancer patients. Onconova Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Onconova Therapeutics's EBIT

Onconova Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Onconova Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Onconova Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Onconova Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Onconova Therapeutics stock

How much did Onconova Therapeutics achieve in EBIT for the current year?

In the current year, Onconova Therapeutics has achieved an EBIT of -24.89 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Onconova Therapeutics.

How has the EBIT of Onconova Therapeutics developed in recent years?

The EBIT of Onconova Therapeutics has increased by 22.613% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Onconova Therapeutics?

The EBIT of Onconova Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Onconova Therapeutics pay?

Over the past 12 months, Onconova Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Onconova Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Onconova Therapeutics?

The current dividend yield of Onconova Therapeutics is .

When does Onconova Therapeutics pay dividends?

Onconova Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Onconova Therapeutics?

Onconova Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Onconova Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Onconova Therapeutics located?

Onconova Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Onconova Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Onconova Therapeutics from 9/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.

When did Onconova Therapeutics pay the last dividend?

The last dividend was paid out on 9/18/2024.

What was the dividend of Onconova Therapeutics in the year 2023?

In the year 2023, Onconova Therapeutics distributed 0 USD as dividends.

In which currency does Onconova Therapeutics pay out the dividend?

The dividends of Onconova Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Onconova Therapeutics

Our stock analysis for Onconova Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Onconova Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.